Zynext Ventures Invests in neuro42, A Company Developing Portable MRI Systems for Neuroimaging and Interventions
Summary
Their compact, user-friendly MRI scanner enables rapid diagnosis, while the robotic module promises to revolutionize procedures like brain biopsies and ablations. neuro42s Diagnostic MRI platform is FDA 510(K) cleared for neuroimaging, and the company is currently seeking regulatory clearance for its interventional module.Jay Kothari, Director of Zynext Ventures, highlighted the investments strategic importance, saying, "neuro42s disruptive technology has the potential to reshape neuroimaging and interventions, enabling precise planning and execution of surgical procedures like shunts, biopsies, and laser therapy. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.